J P Morgan Chase & Co Reiterates “Neutral” Rating for Abcam Plc (ABC)
Abcam Plc (LON:ABC)‘s stock had its “neutral” rating reiterated by equities researchers at J P Morgan Chase & Co in a research report issued to clients and investors on Tuesday. They presently have a GBX 864 ($11.16) price target on the stock. J P Morgan Chase & Co’s price target would indicate a potential downside of 21.24% from the company’s previous close.
A number of other equities analysts have also recently issued reports on ABC. Peel Hunt reaffirmed a “hold” rating and issued a GBX 750 ($9.69) price objective on shares of Abcam Plc in a research note on Friday, August 18th. Berenberg Bank restated a “buy” rating and set a GBX 1,100 ($14.21) price objective on shares of Abcam Plc in a report on Monday. Panmure Gordon restated a “sell” rating on shares of Abcam Plc in a report on Monday. Finally, Numis Securities Ltd restated an “add” rating and set a GBX 1,116 ($14.41) price objective on shares of Abcam Plc in a report on Thursday, July 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of GBX 914 ($11.80).
Shares of Abcam Plc (LON:ABC) opened at 1086.00 on Tuesday. Abcam Plc has a 12 month low of GBX 759.50 and a 12 month high of GBX 1,113.00. The firm’s market cap is GBX 2.20 billion. The stock’s 50 day moving average price is GBX 1,054.69 and its 200-day moving average price is GBX 954.20.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/14/j-p-morgan-chase-co-reiterates-neutral-rating-for-abcam-plc-abc.html.
About Abcam Plc
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
Receive News & Stock Ratings for Abcam Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam Plc and related stocks with our FREE daily email newsletter.